FDBusiness.com

Nestlé Health Science (NHSc) has announced that it will make a further equity investment of US$200 million in Aimmune Therapeutics, a California-based biopharmaceutical company developing and commercializing treatment for potentially life-threatening food allergies. NHSc first invested in Aimmune Therapeutics in 2016, and its total investment to date is US$473 million.

This additional capital will strengthen Aimmune Therapeutics’s financial position as it is preparing for the launch of PALFORZIA, the first medication approved by the United States Food and Drug Administration for food allergies in children and teens. NHSc expects this launch to change the landscape of food allergy treatment.

Investing in food allergy therapies is a natural extension of NHSc’s current pediatric food allergy portfolio which includes its products for babies and young children with Cow’s Milk Protein Allergy (Althéra, Alfaré and Alfamino) and its investment in Before Brands, which makes SpoonfulOne, a nutrition-based, early childhood, food allergy-prevention product.

Nestlé Health Science is a wholly-owned subsidiary of Nestlé and is a globally recognized leader in the field of nutritional science.